EGF vs KGF-1

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.

Binds FGFR2b (the KGF receptor), which is exclusively expressed on epithelial cells — providing tissue-specific action without mesenchymal effects. Activates RAS/MAPK and PI3K/Akt to promote keratinocyte proliferation and migration. Extends the anagen phase of the hair growth cycle.

KGF-1 (keratinocyte growth factor 1; FGF-7) is a member of the fibroblast growth factor family that signals exclusively through the FGFR2b splice variant expressed on epithelial cells, where it acts as a potent mitogen and cytoprotective factor for keratinocytes and mucosal epithelial cells; uniquely paracrine in nature, KGF-1 is produced by stromal cells to maintain adjacent epithelial layer integrity and support mucosal healing. KGF-1 activates FGFR2b to drive epithelial cell proliferation, migration, and differentiation, and to protect mucosal surfaces from damage caused by cytotoxic therapies; this cytoprotective mechanism forms the basis of its clinical application in preventing chemotherapy- and radiation-induced breakdown of the gastrointestinal epithelium, where FGFR2b is highly expressed. A landmark randomized controlled trial published in the New England Journal of Medicine (2004) demonstrated that palifermin — recombinant human KGF-1 (Kepivance, Amgen) — significantly reduced the incidence and duration of severe oral mucositis in hematologic malignancy patients undergoing myelotoxic conditioning for stem cell transplant; this pivotal Phase 3 study established the evidence base for FDA approval in 2004. Palifermin (Kepivance) is FDA-approved and requires a prescription for prevention of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy; it is not approved for cosmetic applications, general wound healing, or skin rejuvenation, and the KGF-1 evidence base is specific to chemotherapy-conditioning mucosal protection in oncology settings.